Keywords: abbott, abt-378/r, efficacy, pi-resistant, patients, new, data
Abbott's ABT-378/r, efficacy in PI-resistant patients
Article | 03 February 2000
New data have shown that Abbott Laboratories' investigational proteaseinhibitor, ABT-378/ritonavir, may suppress viral load in HIV patients who have ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
